LENZ has announced an exclusive licensing and commercialisation agreement with Lotus Pharmaceutical of Taiwan.

Visakhapatnam: A 15-year follow-up of 5,395 participants from the erstwhile combined Andhra Pradesh (encompassing both ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

Research and Development (R&D) Expenses: R&D expenses decreased to $5.8 million for the three months ended March 31, 2025, ...

Most patients were not bothered by most visual disturbances. LOS ANGELES — Patients implanted with a presbyopia-correcting IOL reported high satisfaction after surgery and preserved visual ...

In presbyopia, Krueger said ESWT has shown promise in improving lens elasticity in porcine models. In cataracts, it helped improve lens clarity and lens volume. Krueger said he could see ...

ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to ...

LENZ Therapeutics, Inc.’s LENZ share price has dipped by 5.70%, which has investors questioning if this is right time to buy.

The World Health Organization (WHO) has partnered with the Universal Postal Union (UPU) to expand access to eye care using ...

EXPLORE Health Money Travel Food Style Book Club Classifieds #ZoomerDaily Policy & Perspective Arts & Entertainment Stars & ...

A startup out of Finland is taking a new look at the market for prescription eyewear. Tapping into innovations in ...

LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first ...